TGTX TG THERAPEUTICS, INC.
FY2025 10-K
TG THERAPEUTICS, INC. (TGTX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 27, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Fully integrated biotech focused on novel treatments for B-cell diseases, principally commercializing BRIUMVI for relapsing multiple sclerosis (RMS)
- • New initiatives: Launched Next In MS™ awareness platform with Christina Applegate; initiated Phase 3 enrollment for subcutaneous ublituximab; dosed first patient with azer-cel CAR T therapy in Phase 1 for progressive MS
Management Discussion & Analysis
- • No revenue or profitability data provided in the excerpt
- • No segment performance or cash flow information disclosed
Risk Factors
- • Cybersecurity breach risk impacting drug candidate development and commercialization via failures in internal or third-party CROs, CMOs, or contractors
- • Management oversight of cybersecurity risks with Board receiving regular reports on material threats and IT security effectiveness
Financial SummaryXBRL
Revenue
$616M
Net Income
$447M
Operating Margin
20.0%
Net Margin
72.6%
ROE
69.0%
Total Assets
$1.1B
EPS (Diluted)
$2.77
Operating Cash Flow
-$25M
Source: XBRL data from TG THERAPEUTICS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on TG THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.